Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX)‘s stock had its “buy” rating restated by stock analysts at Jefferies Group LLC in a report issued on Thursday. They currently have a $18.00 price objective on the specialty pharmaceutical company’s stock. Jefferies Group LLC’s target price suggests a potential upside of 27.93% from the company’s current price. Jefferies Group also issued estimates for Valeant Pharmaceuticals International’s FY2017 earnings at $3.45 EPS.

A number of other analysts have also recently commented on the company. Wells Fargo & Company dropped coverage on Valeant Pharmaceuticals International in a research report on Sunday, July 30th. BidaskClub cut Valeant Pharmaceuticals International from a “hold” rating to a “sell” rating in a research report on Friday, June 16th. Scotiabank dropped their price target on Valeant Pharmaceuticals International from $15.00 to $12.00 and set a “sector perform” rating on the stock in a research report on Wednesday, April 26th. Vetr cut Valeant Pharmaceuticals International from a “strong-buy” rating to a “buy” rating and set a $14.82 price target on the stock. in a research report on Monday, May 22nd. Finally, Mizuho reissued an “underperform” rating and issued a $8.00 price target (down from $9.00) on shares of Valeant Pharmaceuticals International in a research report on Monday, April 17th. Four analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $17.26.

Shares of Valeant Pharmaceuticals International (NYSE:VRX) traded up 0.28% on Thursday, reaching $14.11. The company’s stock had a trading volume of 5,567,422 shares. Valeant Pharmaceuticals International has a 12-month low of $8.31 and a 12-month high of $32.74. The company’s 50 day moving average price is $16.61 and its 200 day moving average price is $13.38. The company’s market cap is $4.91 billion.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last posted its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.05 earnings per share for the quarter, topping analysts’ consensus estimates of $0.97 by $0.08. Valeant Pharmaceuticals International had a positive return on equity of 60.62% and a negative net margin of 12.40%. The firm had revenue of $2.23 billion for the quarter, compared to the consensus estimate of $2.23 billion. During the same quarter in the prior year, the business earned ($0.88) EPS. The business’s revenue for the quarter was down 7.7% on a year-over-year basis. Analysts forecast that Valeant Pharmaceuticals International will post $3.89 EPS for the current fiscal year.

WARNING: This news story was first reported by Daily Political and is the property of of Daily Political. If you are reading this news story on another site, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The correct version of this news story can be viewed at https://www.dailypolitical.com/2017/08/10/valeant-pharmaceuticals-international-inc-vrx-receives-buy-rating-from-jefferies-group-llc.html.

Several hedge funds and other institutional investors have recently made changes to their positions in VRX. ValueAct Holdings L.P. increased its position in shares of Valeant Pharmaceuticals International by 20.0% in the first quarter. ValueAct Holdings L.P. now owns 17,997,224 shares of the specialty pharmaceutical company’s stock worth $198,509,000 after buying an additional 3,002,963 shares during the last quarter. Canada Pension Plan Investment Board increased its position in shares of Valeant Pharmaceuticals International by 24,953.6% in the second quarter. Canada Pension Plan Investment Board now owns 2,104,500 shares of the specialty pharmaceutical company’s stock worth $36,525,000 after buying an additional 2,096,100 shares during the last quarter. Saba Capital Management L.P. increased its position in shares of Valeant Pharmaceuticals International by 132.4% in the first quarter. Saba Capital Management L.P. now owns 2,315,900 shares of the specialty pharmaceutical company’s stock worth $25,544,000 after buying an additional 1,319,311 shares during the last quarter. Cannell Peter B & Co. Inc. acquired a new position in shares of Valeant Pharmaceuticals International during the second quarter worth approximately $20,981,000. Finally, Bogle Investment Management L P DE acquired a new position in shares of Valeant Pharmaceuticals International during the first quarter worth approximately $11,223,000. 51.14% of the stock is owned by hedge funds and other institutional investors.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.